Taken together, these data imply that a prebiotic–acetate–FFAR2 molecular circuit prevents NAFLD/NASH progression by ameliorating hepatic insulin resistance and defects in lipid metabolism (Fig. 7). This evidence concerns the gene FFAR2 and metabolic dysfunction-associated steatotic liver disease.